The dual threat: exploring the emergence of human metapneumovirus and SARS-CoV-2 coinfections in respiratory infections.

Abstract

SARS-CoV-2-triggered COVID-19 epidemic has thrown unprecedented challenges at the global public health system but has also drawn attention to the co-circulation of other respiratory viruses, among them human metapneumovirus (hMPV). Both viruses are significant contributors to respiratory illnesses. Human metapneumovirus (hMPV) can cause serious respiratory infections, particularly in young children, elderly, and immunocompromised individuals. This review explores the overlap between human metapneumovirus (hMPV) and SARS-CoV-2, focusing on their epidemiological patterns, clinical manifestations, and the impact of co-infection on disease severity and patient outcomes. We consider the molecular mechanisms of hMPV's interaction with the host immune system, which might have an impact or exacerbate SARS-CoV-2 pathogenicity. The challenges of identifying and treating co-infections are also discussed in this study as are the effects of clinical management during the present pandemic. Furthermore, the possibilities of synergistic effects between the two viruses involved in these coinfections, particularly modified immune response and worsened respiratory outcomes, have been brought up. We address the intersection of these two viral pathogens to provide insights into their combined burden on healthcare systems, underscore the need for improved diagnostic tools, and advocate for research on targeted treatment and vaccine strategies. This review highlights the dual threat posed by hMPV and SARS-CoV-2 and calls for greater attention to the implications of viral co-infections in respiratory diseases.